Език: EN EN
← Назад към резултатите
Активно (без набиране) Фаза 3 NCT05882877

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Фаза 3 – широко изпитване преди одобрение
Заболявания: Atopic Dermatitis

Спонсор: Amgen

Налично на: БГ
Обобщение
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Кой може да участва
Inclusion Criteria: * Completion of an end of treatment duration visit (Week 24 or Week 52 visit for adult or adolescent studies, respectively) in a rocatinlimab parent study (ROCKET-IGNITE, ROCKET-HORIZON, ROCKET-SHUTTLE, ROCKET-ASTRO, ROCKET-ORBIT, OR ROCKET-VOYAGER) within the past 28 days. * Participants from the parent study ROCKET-ORBIT must achieve an improvement in EASI score at week 52 of at least 60% compared to parent study baseline (EASI 60). Exclusion Criteria: * Permanent investigational product discontinuation due to safety-related reasons, protocol-defined stopping rules or conditions/reasons unrelated to efficacy during the rocatinlimab parent study (ROCKET-IGNITE, ROCKET-HORIZON, ROCKET-SHUTTLE, ROCKET-ASTRO, ROCKET-ORBIT, OR ROCKET-VOYAGER), or at the time of Screening or Day 1.
Места на провеждане 38
Argentina (1)
Conexa Investigacion Clinica SA
CABA , Buenos Aires
Австралия (1)
Premier Specialists
Kogarah , New South Wales
Белгия (1)
Universite Catholique de Louvain Cliniques Universitaires Saint Luc
Brussels
Бразилия (1)
Centro do Diagnostico e Pesquisa da Osteoporose do Espirito Santo
Vitória , Espírito Santo
България (1)
Medical Center Asklepii OOD
Dupnitsa
Канада (1)
Dermatology Research Institute Incorporated
Calgary , Alberta
Chile (1)
Hospital Base San Jose de Osorno
Osorno
Китай (1)
Peking University Peoples Hospital
Beijing , Beijing Municipality
Хърватия (1)
Special Hospital for Medical Rehabilitation Naftalan
Ivanić-Grad
Чехия (1)
Kozni ambulance Kutna Hora sro
Kutná Hora
Дания (1)
Gentofte Hospital
Hellerup
Estonia (1)
North Estonia Medical Centre
Tallinn
Финландия (1)
Clinical Research Services Helsinki
Helsinki
Франция (1)
Hopital Prive d Antony
Antony
Гърция (1)
University General Hospital Attikon
Athens
Hong Kong (1)
Queen Mary Hospital, The University of Hong Kong
Hong Kong
Унгария (1)
Trial Pharma Kft
Békéscsaba
Израел (1)
Sheba Medical Center
Ramat Gan
Италия (1)
Universita degli Studi Gabriele D Annunzio di Chieti e Pescara
Chieti
Япония (1)
Aichi Medical University Hospital
Nagakute-shi , Aichi-ken
Latvia (1)
Outpatient clinic Veselibas Centrs 4
Riga
Malaysia (1)
Hospital Sultan Ismail
Johor Bahru , Johor
Mexico (1)
Clínica de Enfermedades Crónicas y de Procedimientos Especiales
Morelia , Michoacán
Нидерландия (1)
Bravis Ziekenhuis
Bergen op Zoom
Полша (1)
ClinicMed Daniluk Nowak Spolka komandytowa
Bialystok
Puerto Rico (1)
Gcm Medical Group, Psc
San Juan
Румъния (1)
Derma Cluj
Cluj-Napoca
Сингапур (1)
National University Hospital
Singapore
Словакия (1)
Fakultna Nemocnica s poliklinikou F D Roosevelta Banska Bystrica
Banská Bystrica
South Africa (1)
Hiway Medical Centre
Westville, Durban , KwaZulu-Natal
Южна Корея (1)
Korea University Ansan Hospital
Ansansi, Gyeonggido
Испания (1)
Hospital Universitario Reina Sofia
Córdoba , Andalusia
Швейцария (1)
Inselspital Bern
Bern
Taiwan (1)
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City
Тайланд (1)
King Chulalongkorn Memorial Hospital
Bangkok
Турция (1)
Ankara Bilkent Sehir Hastanesi
Ankara
Великобритания (1)
Alder Hey Childrens Hospital
Liverpool
САЩ (1)
Cahaba Dermatology and Skin Health Center
Birmingham , Alabama
Технически детайли
Статус
Активно (без набиране)
Фаза
Фаза 3
Вид изследване
INTERVENTIONAL
Пол
Мъже и жени
Минимална възраст
12 Years
Максимална възраст
100 Years
Здрави доброволци
Не
Начална дата
31.05.2023
Крайна дата
30.06.2027
Регистрационен номер
NCT05882877
Източник
anzctr
Запитване за медицински туризъм

Информацията е извлечена автоматично от ClinicalTrials.gov. Консултирайте се с вашия лекар преди да предприемете действия.